GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (NAS:ORTX) » Definitions » Gross Property, Plant and Equipment

Orchard Therapeutics (Orchard Therapeutics) Gross Property, Plant and Equipment : $27.13 Mil (As of Sep. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Orchard Therapeutics Gross Property, Plant and Equipment?

Orchard Therapeutics's quarterly gross PPE declined from Mar. 2023 ($30.05 Mil) to Jun. 2023 ($28.83 Mil) and declined from Jun. 2023 ($28.83 Mil) to Sep. 2023 ($27.13 Mil).

Orchard Therapeutics's annual gross PPE stayed the same from Dec. 2020 ($38.82 Mil) to Dec. 2021 ($35.24 Mil) but then increased from Dec. 2021 ($35.24 Mil) to Dec. 2022 ($37.70 Mil).


Orchard Therapeutics Gross Property, Plant and Equipment Historical Data

The historical data trend for Orchard Therapeutics's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchard Therapeutics Gross Property, Plant and Equipment Chart

Orchard Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 6.97 30.17 38.82 35.24 37.70

Orchard Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.94 37.70 30.05 28.83 27.13

Orchard Therapeutics Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Orchard Therapeutics  (NAS:ORTX) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Orchard Therapeutics Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Orchard Therapeutics's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchard Therapeutics (Orchard Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
245 Hammersmith Road, London, GBR, W6 8PW
Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
Executives
Bobby Gaspar director, officer: See Remarks ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Fmr Llc 10 percent owner, other: See Remark 1 245 SUMMER STREET, BOSTON MA 02210
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Steven Altschuler director MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Jon Ellis director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Plc Glaxosmithkline director, 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Marc Dunoyer director ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
John T Curnutte director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Mark Rothera director, officer: See Remarks C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James A Geraghty director C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139
Alicia Secor director 33 HAYDEN AVE., LEXINGTON MA 02421

Orchard Therapeutics (Orchard Therapeutics) Headlines

From GuruFocus

Orchard Therapeutics Announces Proposed ADS Ratio Change

By sperokesalga sperokesalga 02-10-2023

Orchard Therapeutics to Present at Stifel's Genetic Medicines Day

By sperokesalga sperokesalga 05-24-2023

Kyowa Kirin to Acquire Orchard Therapeutics

By Marketwired 10-05-2023